The brand requires reporting the issue within 48 hours of delivery, with photo evidence of the shipping label, packaging, and medication, which the dispensing pharmacy reviews before issuing a replacement
For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the Refer to: View original content to download multimedia: SOURCE
People who cease taking GLP-1 obesity drugs, which include semaglutide (Wegovy) and tirzepatide (Zepbound), typically regain an average of nearly a pound a month, ultimately gaining back all the weight they lost within two years, according to a review of 37 earlier studies
Understanding Semaglutide: What You Need to Know Semaglutide is an FDA-approved GLP-1 receptor agonist refined for chronic weight management in adults experiencing obesity or being overweight with an additional weight-related condition
Is this program right for you